Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study.

Journal for immunotherapy of cancer·2026

Same author

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.

Annals of the rheumatic diseases·2026

Same author

A comprehensive study of biodegradation and detoxification of triazine-based azo dye (Reactive Red 120) using biofilm-mediated continuous packed-bed bioreactor.

Environmental technology·2025

Same author

Real-World Analysis of Patient Characteristics, Adverse Events, and Economic Burden Among Patients with Giant Cell Arteritis Treated with Glucocorticoids.

Rheumatology and therapy·2025

Same author

Therapeutic Choices in Systemic Sclerosis-Associated Interstitial Lung Disease, a Survey of 2 International Research Groups.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2025

Same author

C. difficile Infection Complicated by a Large Pleural Effusion.

Cureus·2025

Search research articles

Related Experiment Video

Updated: Jul 28, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics.

Michael Macklin¹, Sudeep Yadav¹, Reem Jan¹

¹Section of Rheumatology, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA.

Pharmaceuticals (Basel, Switzerland)

|June 1, 2023

Summary

Immune checkpoint inhibitors (ICI) can cause systemic scleroderma (SSc) and mimics. ICI-SSc differs from primary SSc, and pre-existing SSc may flare after ICI treatment.

Keywords:

autoimmune disease drug toxicities fasciitis immune checkpoint inhibitor morphea systemic sclerosis

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jul 28, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Area of Science:

Oncology
Rheumatology
Immunology

Background:

Immune checkpoint inhibitors (ICIs) are standard cancer therapy.
ICI use is linked to autoimmune complications.
Data on ICI-associated scleroderma is limited.

Purpose of the Study:

To review literature on ICI-associated systemic scleroderma (ICI-SSc).
To analyze differences between ICI-SSc and primary SSc.
To investigate ICI-related scleroderma mimics.

Main Methods:

Systematic literature review.
Analysis of case reports and studies on ICI-SSc and mimics.
Comparison of ICI-SSc features with primary SSc.

Main Results:

ICI-SSc cases showed fewer vascular features and less seropositivity than primary SSc.
Patients with pre-existing SSc may experience flares post-ICI.
ICI-eosinophilic fasciitis cases were identified; ICI-scleromyxedema and ICI-scleroedema were not found.

Conclusions:

ICI-SSc presents differently from primary SSc.
Management of ICI-SSc requires further investigation.
Collaborative, multi-institutional research is crucial for understanding and managing ICI-SSc.